logo-loader
viewNemaura Medical Inc

Nemaura says improved continuous glucose monitor halves time needed for reliable reading

According to Nemaura, a major competitor’s product requires a two-hour ‘warm-up period’

Faz Chowdhury
The flexibility of SugarBEAT will be a key differentiating factor, according to the CEO, Dr Faz Chowdhury

Nemaura Medical Inc (NASDAQ:NMRD) said Thursday that the company has improved its SugarBEAT continuous glucose monitor to halve the time needed for a reliable reading for diabetic and prediabetic patients.

The  Loughborough, England-based medical technology company said in a press release that the time it takes for a reliable reporting of glucose levels from its skin-patch system can be reduced to 30 minutes from about an hour previously.

BIG PICTURE: Nemaura is a red hot medtech stock with a winner in its painless sugarBEAT glucose monitor

According to Nemaura, a major competitor’s continuous glucose monitor requires a two-hour “warm-up period” and is designed to be worn continuously for 10 days.

Nemaura said its advance provides flexibility for users who wish to wear the skin patch for a few hours daily.

“The flexibility of SugarBEAT will be a key differentiating factor with the potential to reach the largest number of diabetics and provides Nemaura with the opportunity to expand into new markets,” Dr Faz Chowdhury, CEO of Nemaura, said in a statement.

Diabetic population

Globally, there are more than 400 million diabetics and 1 billion prediabetics, according to Nemaura, citing PiperJaffray Co data. The annual addressable market for continuous glucose monitors for diabetics is estimated at $82 billion, with the US market estimated at $13 billion.

Shares of Nemaura slipped $0.03 to $1.04 in Thursday’s Nasdaq trading.

Last month, Nemaura announced the closing of a public offering that raised $2 million.

Contact Dennis Fitzgerald at [email protected]

Quick facts: Nemaura Medical Inc

Price: 5.01 USD

NASDAQ:NMRD
Market: NASDAQ
Market Cap: $104.25 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Nemaura Medical Inc named herein, including the promotion by the Company of Nemaura Medical Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Nemaura Medical reveals details of upcoming European launch...

Nemaura Medical Inc (NASDAQ:NMRD) Vice President of Strategy & Strategic Alliances Dr Fred Schaebsdau tells Proactive the medical technology company is targeting a commercial launch for its flagship SugarBEAT continuous glucose monitor in the UK and in Ireland in January 2020. Dr...

on 10/08/2019

2 min read